A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention

American Heart Journal

Volumn 163, Issue 6, 2012, Pages 1019-1023

  Pelliccia, Francesco ^a   Pasceri, Vincenzo ^b   Marazzi, Giuseppe ^c   Rosano, Giuseppe ^c   Greco, Cesare ^a   Gaudio, Carlo ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d Eleonora Lorillard Spencer Cenci Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; PLACEBO; RANOLAZINE; TROPONIN I;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS;

ACETANILIDES; AGED; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PILOT PROJECTS; PIPERAZINES; TROPONIN I;

EID: 84862577191     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.03.018     Document Type: Article

References (20)

1. Brener SJ, Ellis SG, Schneider J, et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002;23:869-76. (Pubitemid 34717422)
2. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol 2003;42:1412-4. (Pubitemid 37267282)
3. Ioannidis JPA, Karvouni E, Katritis DG. Mortality risk conferred by small elevations of creatine-kinase MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 2003;42:1406-11. (Pubitemid 37267281)
4. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8. (Pubitemid 39056265)
5. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011;123:1622-32.
6. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-106. (Pubitemid 40577905)
7. Pelliccia F, Pasceri V, Granatelli A, et al. Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. Am J Cardiol 2006;98:1461-3. (Pubitemid 44779473)
8. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006(Suppl 4):iv6-iv14. (Pubitemid 43974036)
9. Fraser H, Belardinelli L, Wang L, et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006;41:1031-8. (Pubitemid 44791334)
10. Chaitman BR, Skettino SL, Parker JO, et al, for MARISA investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82. (Pubitemid 38496341)
11. Stone PH, Gratsiansky NA, Blokhin A, et al ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-75. (Pubitemid 44093970)
12. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al MERLINTIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-83. (Pubitemid 46658646)
13. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53:1510-6.
14. Waters D, Lespérance J, Craven TE, et al. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis: implications for clinical trials. Circulation 1993(87-Suppl II):38-47.
15. Uettwiller-Geiger D, Wu AH, Apple FS. Multicenter evaluation of an automated assay for troponin I. Clin Chem 2002;48:869-76. (Pubitemid 34587586)
16. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
17. Heusch G, Kleinbongard P, Böse D, et al. Coronary microembolization from bedside to bench and back to bedside. Circulation 2009;120:1822-36.
18. Aldakkak M, Camara AK, Heisner JS, et al. Ranolazine reduces Ca(2+) overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res 2011;64:381-92.
19. Deshmukh SH, Patel SR, Pinassi E, et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009;20:343-7.
20. Nieminen T, Tavares CA, Pegler JR, et al. Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model. Circ Cardiovasc Interv 2011;4:481-7.